Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial.

Background : Bloodstream infections caused by bacteria with carbapenem resistance are associated with high mortality. Cefiderocol has broad in vitro activity against carbapenem-resistant Gram-negative bacilli. We aimed to assess whether cefiderocol was non-inferior or superior to standard-of-car...

Full description

Bibliographic Details

Main Authors:	Paterson, David L, Sulaiman, Helmi, Liu, Po-Yu, Chatfield, Mark D, Yilmaz, Mesut, Salmuna, Zeti Norfidiyati, Mazlan, Mohd Zulfakar, Anunnatsiri, Siriluck, Sirijatuphat, Rujipas, Chotiprasitsakul, Darunee, Lye, David C, Somani, Jyoti, Kalimuddin, Shirin, Aslan, Abdullah T, Thamlikitkul, Visanu, Lee, Yi-Tzu, Yang, Ya-Sung, Lin, Yi-Tsung, Wan Ramli, Wan Nurliyana, Tseng, Chien-Hao, Archuleta, Sophia, Chan, Yvonne Fu Zi, Forde, Brian M, Wright, Hugh, Stewart, Adam G, Ramsay, Kay A, Ling, Weiping, Rossi, Vicki, Harris-Brown, Tiffany M, Harris, Patrick N A
Format:	Article
Language:	en en
Published:	Elsevier Ltd 2026
Subjects:	RC111 Infectious and Parasitic Diseases
Online Access:	http://irep.iium.edu.my/123591/7/Scopus%20-%20Document%20Details.pdf http://irep.iium.edu.my/123591/8/123591_Cefiderocol_versus_standard_therapy_for_hospital_acquired_and_health.pdf http://irep.iium.edu.my/123591/ https://doi.org/10.1016/S1473-3099(25)00469-4
Tags:	Add Tag No Tags, Be the first to tag this record!